Industry news

Patent Cliff Means Pharmaceutical Companies Will Lose $65 Billion by 2019, says GlobalData

GlobalDate

Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData.

2013 New Molecular Enterties Summary Report (Charts) - FDA

U.S. Food and Drug Administration

The charts below are pulled from the 2013 Novel New Drug Summary Report. 

New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products of 2014

U.S. Food and Drug Administration

Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. With its understanding of the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new products are designed to treat, FDA provides scientific and regulatory advice needed to bring new therapies to market.

Returns on pharmaceutical R&D improving as pipelines revive

Ben Hirschler, Reuters

Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development (R&D) increasing for the first time since 2010.

Long-term painkiller use on the rise, with more patients taking dangerous combos

Emily Wasserman, FiercePharma

Amid growing controversy over prescription painkillers, a new study shows that patients who are prescribed opioids continue to use them over a long period of time, indicating potential abuse. The report could add fuel to the fire as lawmakers and industry groups continue to battle companies producing the drugs.

Panel: How to understand the long biotech boom?

Stacy Lawrence, FierceBiotech

Fundamental scientific and patient advances, as well as the investors who embrace them, have transformed biotech in just the last few years. As this has coincided with a broader resurgence in the stock market, industry valuations have skyrocketed.

Hackers use Wall Street know-how to steal stock-moving biotech info

Nick Paul Taylor / Fierce Biotech

Biotech IT security teams were just presented with another headache. A team of Western, Wall Street insiders is believed to be breaking into biopharma company emails in pursuit of information on drug development results, takeovers and other events likely to affect share price.

Russia Develops Four Ebola Vaccines: Health Minister

Sputnic

Four vaccines against the Ebola virus are currently being developed by Russian scientists, one of them is already undergoing clinical tests, Russian Health Minister Veronika Skvortsova said Thursday. "We started developing the rest not long ago, when the outbreak was at its peak. We expect them to be ready for trials in February 2015,” she said.

The rise of the Silicon Valley biocomputing startup

Nick Paul Taylor / Fierce Biotech

The growing need for computer-enabled capabilities in drug development has led to the creation of biotech-focused software startups trying to replicate the success of the likes of Medidata ($MDSO). And the obvious base for these startups is the one part of the U.S. where biotech and tech hubs are co-located: San Francisco.

India wants in on the biotech hub trend

Damian Garde / Feirce Biotech

India should take a cue from the biotech hotbeds of the U.S. and U.K., a local trade groups says, investing in infrastructure to help foster startups and grow innovation clusters of its own.